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Opportunities to improve the care of patients with kidney trans- ESRD experience significant morbidity and mortality.
plant failure. In 1998, the life expectancy for a male dialysis patient
Background. Patients initiating dialysis after a failed kidney aged 40 to 44 years in the United States was only 7.2transplant are a subgroup of chronic kidney disease (CKD) pa-
years [1]. ESRD patients also consume a large amounttients who have not been characterized. Exposure to immuno-
of health care resources. Total Medicare ESRD expendi-suppressive medications differentiates these patients from the
general incident end-stage renal disease (ESRD) population. tures were 12 billion dollars in 1998 and are projected
Methods. Data from the Health Care Financing Administra- to exceed 28 billion dollars by the year 2010 [1].
tion 2728 form were used to determine the hematocrit, erythro- The cost of ESRD care is particularly high during thepoietin use, serum albumin and glomerular filtration rate (GFR)
first few months after dialysis initiation, and is probablyamong 4643 patients with failed kidney transplants who initi-
in part a consequence of suboptimal care prior to ESRD.ated dialysis between April 1995 and December 1998.
Results. At dialysis initiation, the mean hematocrit, serum Indeed, we have previously shown that the care of pa-
albumin and GFR were 27.5%, 3.3 g/dL, and 8.4 mL/min/ tients with chronic kidney disease (CKD) prior to ESRD
1.73 m2, respectively, and only 35% of patients had received
is poor. In an analysis of patients who began dialysis inerythropoietin. In a multivariate analysis, patients 45 years,
the United States between 1995 and 1997, 60% of patientsfemales, patients of non-White race, non-diabetic patients, he-
modialysis patients and patients with a lower serum albumin had a serum albumin below the lower limit of normal,
had a higher odds for hematocrit 30%. Erythropoietin use 51% had a hematocrit less than 28% and only 23% had
was associated with female gender, White race, increased time received erythropoietin prior to the start of dialysis [2].since transplantation, being employed, peritoneal dialysis, and
Patients with a failed kidney transplant constitute anhigher serum albumin. Patients 45 years and patients with
important proportion of all patients who begin ESRDdiabetes or congestive heart failure had higher odds for hypoal-
buminemia, while employed patients, peritoneal dialysis pa- treatment and comprise 20 to 25% of all patients awaiting
tients, patients with higher hematocrit and patients who had transplantation [3]. Exposure to immunosuppressive med-
received erythropoietin had lower odds of hypoalbuminemia.
ications is an important feature that distinguishes theseConclusions. Despite being known to specialty physicians,
patients from the general incident dialysis population.patients with failed kidney transplants initiate dialysis at levels
of hematocrit, serum albumin, and GFR that may be subopti- Immunosuppressive medications may increase the risk
mal and similar to those in the general incident ESRD popula- for infection, cardiovascular disease, malignancy, and
tion. Socioeconomic factors remain important barriers to the pro- bone marrow suppression in these patients [4–7].vision of CKD care even among these patients with established
In addition, in contrast to the majority of the incidentspecialty physician contact. Improved CKD care could improve
dialysis population, failed transplant patients are knownthe outcomes of this unique subgroup of CKD patients.
to physicians with expertise in CKD care long before
dialysis is required. Therefore, it is reasonable to expect
The incidence of end-stage renal disease (ESRD) is these patients to receive superior CKD care compared to
increasing and is projected to rise to over 170,000 patients the general incident ESRD population. Indeed, specialty
by the year 2010 in the United States [1]. Patients with care prior to dialysis initiation is associated with an in-
formed selection of dialysis modality [8, 9], timely place-
ment of appropriate dialysis access [10], lower morbidityKey words: anemia, hypoalbuminemia, erythropoietin, glomerular fil-
tration rate, kidney transplant, chronic kidney disease. [8], less frequent and shorter hospital stays [10], better
rehabilitation [11], lower costs [10], and possibly lowerReceived for publication October 10, 2001
mortality [12–14].and in revised form January 23, 2002
Accepted for publication January 24, 2002 However, to date, there is a paucity of data on the
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patients with a failed kidney transplant returning to dial- and serum creatinine were 0.5 to 6 g/dL, 10 to 50% and
2.0 mg/dL, respectively. GFR at dialysis initiation wasysis. To determine the clinical characteristics of this
unique subgroup of CKD patients and to gain insight estimated with an equation derived from the Modifica-
tion of Diet in Renal Disease (MDRD) Study, which isinto the quality of CKD care they received, we studied
the level of hematocrit, erythropoietin use, serum albu- based on age, gender, race and serum creatinine level
(abstract; Levey et al, J Am Soc Nephrol 11:155, 2000).min and estimated glomerular filtration rate (GFR) at
dialysis initiation of patients returning to dialysis with a For comparison, the characteristics of the adult (18
years) general incident ESRD population, which in-failed transplant in the United States during the period
between 1995 and 1998. cludes hemodialysis, peritoneal dialysis and pre-emptive
transplant patients, who initiated renal replacement ther-
apy during the same time period were determined.
METHODS
Patient population Analytical methods and statistical analysis
Patient characteristics at the time of dialysis initiationWe studied all adult patients (18 years of age) who
returned to dialysis after a failed kidney transplant for were described as the mean and standard deviation for
continuous variables and frequency for categorical vari-whom a new 2728 form was completed and included
in the 1999 update of the Medical Evidence Standard ables. Patients were classified as having received erythro-
poietin if any exposure to erythropoietin prior to dialysisAnalysis File (Medevid file) of the United States Renal
Data System (USRDS). The new version of the Health initiation had been indicated on the 2728 form. Patients
were classified as hypoalbuminemic if the recorded se-Care Financing Administration (HCFA) 2728 form was
adopted in April 1995 and therefore only patients who rum albumin on the 2728 form was 3.5 g/dL. The char-
acteristics of the study patients and general incident dial-returned to dialysis between April 1, 1995 and December
31, 1998 were included in the analysis. Patients with more ysis patients were compared with Chi-squared tests for
categorical variables and t tests for continuous variables.than one 2728 form and patients with invalid USRDS
identification numbers were excluded. To avoid the in- The univariate associations of clinical and laboratory
factors with hematocrit 30%, exposure to pre-dialysisclusion of patients who were acutely unwell with either
acute rejection or peri-operative events, patients with erythropoietin and hypoalbuminemia were determined
using logistic regression. Variables assessed included pa-grafts that functioned for less than one year also were
excluded from the study. tient age, which was explored as both a continuous and
categorical variable (45 years or 45 years, cut pointThe Medevid file contains all data from the HCFA
2728 form. This form is completed by the dialysis or based on the distribution of patient age), gender, race
(White versus non-White), diabetes, years since transplan-transplant center for all patients beginning ESRD treat-
ment (dialysis or transplantation) regardless of whether tation, type of insurance (private versus non-private),
employment status (employed full or part time versusthey are covered by Medicare. For failed transplant pa-
tients returning to dialysis, a new 2728 form is required not), dialysis modality, history of congestive heart fail-
ure, history of ischemic heart disease, hematocrit, serumonly for those patients applying for ESRD Medicare
coverage. During the study period, most transplant recip- albumin and GFR.
Separate stepwise logistic regression analyses wereients were eligible for ESRD Medicare coverage for
three years after the time of transplant. Therefore, the performed to determine factors associated with hemato-
crit 30%, pre-dialysis erythropoietin use and hypoal-majority of patients identified for inclusion in the study
included those who had become Medicare ineligible as buminemia. An a priori decision was made to include
patient age, race, and gender in these models. Additionala result of having received a transplant for greater than
three years and were re-applying for ESRD Medicare. variables were eligible for inclusion in the models based
on univariate association (P  0.10) with the outcomeThe 2728 form contains information on patient demo-
graphics, insurance status, co-morbid conditions, cause of interest. Patients with missing data for any of the
covariates entered in the models were excluded. No at-of ESRD, pre-ESRD recombinant human erythropoie-
tin use, employment status, ESRD treatment modality tempt to impute missing data was made. All analyses
were performed using SAS version 8.1 (SAS Instituteand laboratory information. The laboratory information
is obtained within 45 days before dialysis initiation and Inc., Cary NC, USA).
includes serum creatinine, blood urea nitrogen, hemo-
globin, hematocrit, serum albumin and the dates that
RESULTS
these tests were obtained. Laboratory values that were
Patient characteristicsnot obtained within 45 days prior to dialysis initiation
as well as missing and out of range values were excluded. Among 5054 patients who returned to dialysis between
April 1, 1995 and December 31, 1998, 4643 met inclusionAcceptable ranges for serum albumin, serum hematocrit
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Table 1. Demographic and clinical characteristics of patients at
initiation of renal replacement therapya
Failed kidney Incident end-stage
transplant patients renal disease patients
N  4643b N  233,190b
Age years 4312 6116
Gender male 59% 53%
Race
White 66% 61%
African-American 27% 30%
Otherc 7% 9%
Cause of renal disease
Diabetes 18% 40%
Hypertension 18% 25%
Glomerular disease 32% 13%
Fig. 1. Serum hematocrit among 3818 patients with failed kidney trans-Polycystic kidney
plants and 192,372 general incident ESRD patients. The mean  stan-disease 5% 2%
dard deviation of hematocrit was 27.5  5.9% in patients with a failedOther 27% 16%
kidney transplant and 28.0  5.4% in general incident ESRD patients.Comorbid disease
Symbols are: () patients with a failed kidney transplant; () generalHistory of ischemic
incident ESRD patients.heart disease 11% 24%
History of congestive
heart failure 18% 34%
Diabetes 22% 40%
Time since transplant
years 6.94.4 N/Ad had a higher percentage of males, were more likely to
Insurance
be of White race, had fewer co-morbid diseases, werePrivate 18% 15%
Medicare 29% 22% more likely to be employed and were more likely to
Medicaid 28% 23% initiate peritoneal dialysis. The mean time since trans-
Other 22% 33%
plantation in study patients was 6.9  4.4 years.None 3% 7%
Employment status
Employed (full or Hematocrit and erythropoietin use
part time) 23% 10%
Hematocrit was available for 3818 (82%) of the studyNot employede 77% 90%
Dialysis modality patients and almost all (N  3807) also had information
Hemodialysis 84% 88% regarding pre-dialysis erythropoietin use. The mean he-
Peritoneal dialysis 16% 12%
matocrit in study patients (27.5  5.9%) was clinicallyPre-dialysis erythro-
poietin use 35% 24% similar to that in the general incident ESRD patients
Laboratory values (28.0 5.4%; Table 1). Figure 1 shows the distribution of
Hematocrit % 27.55.9% 28.05.4%
serum hematocrit in study patients and general incidentSerum albumin g/dL 3.30.6 3.20.6
Glomerular filtration ESRD patients. Overall, 67% of the study patients and
rate mL/min/1.73 m2 8.43.9 7.83.8 65% of the general incident ESRD patients had a hema-
a P  0.001 for all comparisons between failed transplant and incident end- tocrit30%. As shown in Table 2, the prevalence of hema-
stage renal disease patients
tocrit 30% was higher among younger patients, females,b The number of patients in whom data was available varied slightly for differ-
ent characteristics African Americans, patients without diabetes or a his-c Other includes Asian, Pacific Islander, MidEast, Indian Sub Continent, Un-
tory of ischemic heart disease, patients initiating hemodi-known, Other/Multiracial
d N/A, not applicable alysis and patients with hypoalbuminemia. In multivari-e Includes retired due to age/preference, retired due to disability, student,
ate analysis (Table 3), female gender was associated withhomemaker, medical leave of absence
a higher odds of hematocrit30%, while age45 years,
White race, diabetes, peritoneal dialysis and a higher
criteria. The 411 patients were excluded because of age serum albumin had lower odds for hematocrit 30%.
under 18 years (N  141), return to dialysis within one Predialysis erythropoietin use was higher among study
year of transplantation (N  223), and duplicate 2728 patients (35%) compared to general incident ESRD pa-
forms or missing USRDS identification numbers (N  tients (24%; Table 1). As shown in Figure 2, pre-dialysis
47). Excluded patients were younger (mean age 32.7  erythropoietin use among study patients was similar at
17 years) and less likely to have diabetes (12%), but were all levels of serum hematocrit. In contrast, the general
otherwise similar to study patients (data not shown). incident ESRD patients had higher erythropoietin use at
The demographic and clinical characteristics of the higher hematocrit levels. The prevalence of pre-dialysis
study patients and general incident dialysis patients (N erythropoietin use was higher among females, white pa-
233,190) are shown in Table 1. Compared to the general tients, employed patients, patients initiating peritoneal
dialysis and patients without hypoalbuminemia (Tableincident ESRD patients, the study patients were younger,
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Table 2. Prevalence of hematocrit 30%, pre-dialysis erythropoietin use and hypoalbuminemiaa among patients who initiated dialysis after
kidney transplant failureb
Hematocrit Pre-dialysis
30% erythropoietin use Hypoalbuminemia
Age years
18–44 71% 35% 50%
45–64 63% 34% 62%
65 56% 37% 71%
Gender
Male 65% 31% 57%
Female 70% 40% 54%
Race
White 66% 38% 55%
African American 71% 28% 58%
Otherc 65% 33% 59%
Cause of renal disease
Diabetes 60% 32% 63%
Hypertension 69% 31% 58%
Glomerular disease 70% 38% 53%
Polycystic kidney disease 58% 33% 63%
Other 69% 35% 51%
Comorbid disease
History of ischemic heart disease 60% 34% 64%
No history of ischemic heart disease 68% 35% 55%
History of congestive heart failure 66% 34% 66%
No history of congestive heart failure 67% 35% 53%
Diabetes 59% 35% 65%
No diabetes 69% 35% 53%
Insurance
Private 66% 42% 49%
Medicare 66% 36% 61%
Medicaid 70% 30% 54%
Other 64% 37% 58%
None 76% 22% 46%
Employment status
Employed (full or part time) 66% 40% 49%
Not employedd 67% 34% 58%
Dialysis modality
Hemodialysis 68% 32% 58%
Peritoneal dialysis 60% 47% 43%
Hematocrit 30% N/Ae 34% 57%
Hematocrit 30% N/Ae 36% 52%
Hypoalbuminemia 68% 33% N/Ae
No hypoalbuminemia 64% 40% N/Ae
Received pre-dialysis erythropoietin 66% N/Ae 51%
No pre-dialysis erythropoietin 68% N/Ae 58%
a Serum albumin 3.5 g/dL
b Based on 4643 patients
c Other includes Asian, Pacific Islander, MidEast, Indian Sub Continent, Unknown, Other/Multiracial
d Includes retired due to age/preference, retired due to disability, student, homemaker, medical leave of absence
e N/A, not applicable
2). In multivariate analysis (Table 3), female gender, albumin less than 3.5 g/dL. As shown in Table 2, the
white race, increased time since transplantation, being prevalence of hypoalbuminemia was higher among older
employed, peritoneal dialysis and a higher serum albu- patients, diabetic patients, patients with a history of isch-
min were associated with a higher odds of receiving pre- emic heart disease or congestive heart failure, unem-
dialysis erythropoietin. ployed patients, patients initiating hemodialysis, patients
with a hematocrit 30% and patients without pre-dial-Serum albumin
ysis erythropoietin use. In multivariate analysis (TableSerum albumin was available for 3160 (68%) of the
3), age 45 years, diabetes and congestive heart failurepatients. The mean serum albumin was 3.3  0.6 g/dL
were associated with a higher odds of hypoalbuminemia,compared to 3.2 0.6 g/dL in the general incident ESRD
while being employed, peritoneal dialysis, a higher serumpatients (Table 1). The distribution of serum albumin is
hematocrit and pre-dialysis erythropoietin use were as-shown in Figure 3. Overall, 55% of study patients and
63% of the general incident ESRD patients had a serum sociated with a lower odds of hypoalbuminemia.
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Table 3. Factors associated with hematocrit 30%, pre-dialysis erythropoietin use and hypoalbuminemia among patients who initiated
dialysis after kidney transplant failurea
Hematocrit 30% Predialysis erythropoietin Hypoalbuminemiab
N  3818 N  3114 N  3160
OR (95% CI)c
Age 45 years ref. 45 years 0.67 (0.57–0.79) 1.05 (0.89–1.23) 1.53 (1.32–1.78)
Female ref. male 1.23 (1.05–1.45) 1.42 (1.21–1.66) 0.97 (0.83–1.11)
White ref. non-white 0.83 (0.70–0.97) 1.22 (1.04–1.44) 0.98 (0.84–1.14)
Diabetes ref. non-diabetic 0.68 (0.57–0.82) 1.36 (1.14–1.63)
History of congestive heart failure 1.32 (1.08–1.62)
Time since transplant per year 1.04 (1.02–1.06)
Employed ref. not employed 1.40 (1.17–1.67) 0.84 (0.69–0.96)
Peritoneal dialysis ref. hemodialysis 0.79 (0.63–0.95) 1.58 (1.29–1.93) 0.70 (0.58–0.84)
Hematocrit per 1% higher N/Ad 0.98 (0.97–0.99)
Albumin per g/dL higher 0.78 (0.69–0.89) 1.24 (1.09–1.41) N/Ad
Pre-dialysis erythropoietin ref. none N/Ad 0.72 (0.63–0.83)
a The odds ratios for variables significant in multivariate analysis and variables a priori chosen for inclusion in the models are shown
b Hypoalbuminemia defined as serum albumin 3.5 g/dL
c OR, odds ratio; CI, confidence interval
d N/A, not applicable
Fig. 2. Pre-dialysis erythropoietin use at different levels of hematocrit
among 3807 patients with a failed kidney transplant () and 192,372 Fig. 4. Glomerular filtration rate at dialysis initiation among 4097 pa-
general incident ESRD patients ( ). Overall, 35% of patients with a tients with a failed kidney transplant () and 210,713 general incident
failed kidney transplant and 24% of general incident ESRD patients ESRD patients ( ). The mean  standard deviation of GFR was 8.4
received erythropoietin. 3.9 mL/min/1.73 m2 in patients with a failed kidney transplant and 7.8
3.8 mL/min/1.73 m2 in general incident ESRD patients.
Glomerular filtration rate
The GFR could be estimated in 4097 (88%) of the
study patients. The mean  SD glomerular filtration
rate at dialysis initiation was 8.4  3.9 mL/min/1.73 m2
compared to 7.8 mL/min/1.73 m2 in the general incident
ESRD patients (Table 1). The distribution of GFR is
shown in Figure 4. Overall, 75% of study patients initi-
ated dialysis at a GFR less than 10 mL/min/1.73 m2 and
16% at a GFR less than 5 mL/min/1.73 m2. In compari-
son, 80% of general incident ESRD patients initiated
dialysis at a GFR less than 10 mL/min/1.73 m2, and 20%
had a GFR less than 5 mL/min/1.73 m2. There was noFig. 3. Serum albumin level at initiation of dialysis among 3160 patients
with a failed kidney transplant () and 161,869 general incident ESRD significant difference in GFR between study patients
patients ( ). The mean  standard deviation of serum albumin was who initiated hemodialysis or peritoneal dialysis. Dia-3.3  0.6 g/dL in patients with a failed kidney transplant and 3.2  0.6
g/dL in general incident ESRD patients. betic study patients initiated dialysis at a higher GFR
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(mean GFR 9.6 mL/min/1.73 m2) compared to non-dia- persist for up to three years [17, 19]. Factors that may
contribute to the development of iron deficiency afterbetic patients (mean GFR 8.0 mL/min/1.73 m2; P 
0.002). transplantation include perioperative blood loss, fre-
quent blood sampling, marrow suppressant drugs, and
high iron demands [16]. The use of serum ferritin levels
DISCUSSION
alone in a setting of chronic inflammation may lead to
This study demonstrates that patients with a failed under-recognition of iron deficiency in this population
kidney transplant initiate dialysis at a mean hematocrit [16]. A higher prevalence of iron deficiency is one possi-
(27.5%), serum albumin (3.3 g/dL) and estimated GFR ble explanation for the observed higher prevalence of
(8.4 mL/min/1.73 m2) that are low and similar to mean anemia despite more frequent erythropoietin use among
levels in the general incident ESRD population in the female patients. As the prevalence of iron deficiency in
United States. These data suggest that even among pa- this study could not be assessed, this issue warrants fur-
tients who are presumed to be under the care of nephrol- ther investigation.
ogists or transplant physicians, CKD care is suboptimal. We determined factors associated with a hematocrit
In addition, this study demonstrates that socioeconomic less than 30%, because hematocrit below this level has
factors such as race and employment status continue to been associated with decreased survival in dialysis pa-
be important determinants of access to medical therapies, tients [20, 21]. In multivariate analysis, the association
such as pre-dialysis erythropoietin, even among patients of younger age and the absence of diabetes with a hema-
who are known to physicians prescribing these therapies. tocrit30% suggests that anemia is under-treated among
The mean hematocrit among patients with a failed kid- patients who may be perceived to be healthier. Indeed,
ney transplant was 27.5%, and was not clinically different the perception that failed transplant patients are health-
from that in the general incident ESRD population ier and able to tolerate anemia better than non-trans-
(28.0%). The hematocrit was the same in both patient plant patients may partly explain the high prevalence of
groups, despite the higher use of pre-dialysis erythropoi- anemia observed in this study.
etin among patients with a failed kidney transplant (35 Of interest, pre-dialysis erythropoietin use was not
vs. 24%). There are a number of factors that may make associated with clinical characteristics such as hematocrit
the treatment of anemia in transplant recipients more level or a history of co-morbid disease. Instead, pre-
difficult and therefore may have contributed to the high dialysis erythropoietin use was associated with socioeco-
prevalence of anemia among these patients. The presence nomic factors such as race and employment status and
of a chronic inflammatory state and the use of immuno- with initiation of peritoneal dialysis. Pre-dialysis erythro-
suppressive medications may theoretically decrease eryth- poietin use and other indices of CKD care have been
ropoietin efficacy in transplant patients [15]. However, previously associated with socioeconomic factors [2].
there is no convincing evidence for higher erythropoietin The influence of socioeconomic factors on CKD care
requirements or treatment resistance in this population may in part be due to inability or unwillingness to seek
[16–18]. Although information regarding erythropoietin medical care because of cultural or economic reasons
dosing was not available in this study, the facts that [22]. However, the results of this study demonstrate that
erythropoietin use was similar at all levels of serum he- socioeconomic factors continue to be important determi-
matocrit and that the majority of patients in this study nants of CKD care even among patients with established
had not received erythropoietin suggest that non-treat- access to specialty physicians. Therefore, other factors,
ment rather than treatment resistance was a more impor- such as the level of communication between physician
tant factor contributing to the high prevalence of anemia. and patient, patient education, and ethnic variation in
Fear of exacerbating renal decline or hypertension may acceptance of medical advice also may be important
have contributed to the low erythropoietin use in these [23, 24]. The association of peritoneal dialysis with pre-
patients. However, available data suggest no deleterious dialysis erythropoietin use is consistent with previous
effect of erythropoietin on the rate of renal decline. observations that patients who initiate peritoneal dialysis
Similarly, although exacerbation of hypertension is pos- also receive more aggressive CKD care [10].
sible with erythropoietin use, most cases are readily The mean serum albumin in study patients (3.2 g/dL)
treated with an adjustment of antihypertensive medica- was similar to that in the general incident ESRD popula-
tions [15, 16]. tion (3.3 g/dL). Hypoalbuminemia has been shown to be
The contribution of iron deficiency to the development an independent predictor of death in transplant patients
of anemia in patients with failing renal transplants may [25]. Consistent with this observation, many of the fac-
be more pronounced than in the general CKD popula- tors associated with hypoalbuminemia could be consid-
tion. The available literature on iron metabolism in trans- ered measures of disease severity (increased age, diabetes,
plant recipients suggests that iron deficiency is common congestive heart failure). The etiology of hypoalbumi-
nemia in the failing transplant population is multifacto-early after transplantation and that abnormalities may
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rial and may be more complex than in the general CKD In conclusion, the results of this study demonstrate
population. Factors including malnutrition, exposure to that the provision of CKD care in patients with failed
corticosteroids, volume overload, chronic inflammation, kidney transplants is suboptimal in the United States.
and infection may contribute to the development of hy- Although both patients and physicians would like to
poalbuminemia in this population [25]. The high preva- sustain graft function for as long as possible, this should
lence of hypoalbuminemia in this study and the fact that not prevent the provision of appropriate CKD care. It
multiple factors may contribute to the development of must be recognized that not only the smooth transition
hypoalbuminemia in these patients highlights the impor- to dialysis, but also outcomes after dialysis may depend
tance of ongoing assessment of nutritional status and upon aggressive treatment during the pre-ESRD period.
timely intervention in order to prevent malnutrition.
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